Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Raffi F et al, Lancet Infect Dis. 2013 Nov;13(11):927-35 Posted on December 7th, 2013 - Pr François Raffi Back to Home page
Back to Home page